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Abstract 
Background: Patients with both diabetes mellitus (DM) and chronic kidney disease (CKD) are a subpopulation char‑
acterized by ultrahigh ischemic and bleeding risk after percutaneous coronary intervention. There are limited data on 
the impact of ticagrelor monotherapy among these patients.
Methods: In this post hoc analysis of the GLOBAL‑LEADERS trial, the treatment effects of the experimental (one‑
month dual‑antiplatelet therapy [DAPT] followed by 23‑month ticagrelor monotherapy) versus the reference regi‑
men (12‑month DAPT followed by 12‑month aspirin alone) were analyzed according to DM/CKD status. The primary 
endpoint was a composite endpoint of all‑cause death or new Q‑wave myocardial infarction at 2‑years. The patient‑
oriented composite endpoint (POCE) was defined as the composite of all‑cause death, any stroke, site‑reported MI 
and any revascularization, whereas net adverse clinical events (NACE) combined POCE with BARC type 3 or 5 bleeding 
events.
Results: At 2 years, the DM + /CKD + patients had significantly higher incidences of the primary endpoint (9.5% 
versus 3.1%, adjusted HR 2.16; 95% CI [1.66–2.80], p < 0.001), BARC type 3 or 5 bleeding events, stroke, site‑reported 
myocardial infraction, all revascularization, POCE, and NACE, compared with the DM‑/CKD‑ patients. Among the 
DM + /CKD + patients, after adjustment, there were no significant differences in the primary endpoints between the 
experimental and reference regimen; however, the experimental regimen was associated with lower rates of POCE 
(20.6% versus 25.9%, HR 0.74; 95% CI [0.55–0.99], p = 0.043,  pinteraction = 0.155) and NACE (22.7% versus 28.3%, HR 0.75; 
95% CI [0.56–0.99], p = 0.044,  pinteraction = 0.310), which was mainly driven by a lower rate of all revascularization, as 
compared with the reference regimen. The landmark analysis showed that while the experimental and reference 
regimen had similar rates of all the clinical endpoints during the first year, the experimental regimen was associated 
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Background
Patients with coronary artery disease (CAD) and con-
comitant diabetes mellitus (DM) or chronic kidney 
disease (CKD) are more susceptible to major adverse 
cardiovascular and cerebrovascular events [1]. Moreover, 
the presence of these risk factors is also associated with 
an increased risk of bleeding complications [2, 3]. DM 
and CKD frequently co-exist and given that DM is a well-
established risk factor for renal dysfunction [2, 4], it is 
predicted that nearly 25% of DM patients have CKD [5].
Previously, a subgroup analysis of the PLATO study 
has demonstrated that in the acute coronary syndrome 
(ACS) population, those who had both DM and CKD 
were associated with a drastically unfavorable prognosis 
compared to those having one or neither of these comor-
bidities [6], and among the patients with both DM and 
CKD, the combination of ticagrelor with aspirin substan-
tially reduced cardiovascular death, myocardial infarc-
tion (MI), or stroke compared with clopidogrel plus 
aspirin; however, the dual antiplatelet therapy (DAPT) 
with ticagrelor had a higher rate of TIMI non-CABG-
related major bleeding events.
In an attempt to mitigate bleeding risk while preserving 
the anti-ischemic efficacy, the “aspirin-free” antiplatelet 
strategy has been advocated [7–10]. The first and largest 
trial to date evaluating this concept -GLOBAL LEADERS, 
failed to show the superiority of ticagrelor monotherapy 
over standard DAPT in an all-comer patient population 
(in terms of all-cause mortality or new Q-wave MI) [7]. 
Nevertheless, understanding the impact of ticagrelor 
monotherapy after PCI in patients with DM and CKD in 
this large all-comer contemporary trial is still of clinical 
interest. The ever-growing prevalence of CKD in patients 
with DM [11, 12] underscores the need to specifically 
investigate the effects of different antiplatelet strategies in 
these ultrahigh risk patients.
On this background, here we report the results of a 
post hoc analysis of the GLOBAL LEADERS trial, in 
which we compared the outcomes of patients according 
to the presence or absence of DM and CKD, and also ana-
lyzed the effects of the experimental strategy (1-month 
DAPT followed by 23-month ticagrelor monotherapy) 
compared to the reference strategy (12-month DAPT fol-
lowed by aspirin monotherapy for 12 months) after PCI 
in such defined subgroups.
Methods
The present study is a post hoc subgroup analysis of the 
GLOBAL LEADERS trial. GLOBAL LEADERS trial is a 
prospective, multi-center, randomized controlled trial 
(NCT01813435), which enrolled a total of 15,991 patients 
at 130 hospitals in 18 countries (Europe, Asia, Brazil, 
Australia and, Canada) between July 2013 and Novem-
ber 2015, and aimed to evaluate two antiplatelet strate-
gies after PCI using bivalirudin and biolimus A9-eluting 
stents (Biomatrix) in an all-comers population [13]. 
Details of the study have been previously described. In 
brief, the experimental treatment strategy comprised 
aspirin 75–100 mg once daily in combination with tica-
grelor 90 mg twice daily for one month, followed by tica-
grelor 90 mg twice daily alone for 23 months (irrespective 
of clinical presentation). The reference treatment strategy 
included aspirin 75–100  mg daily in combination with 
either clopidogrel 75 mg once daily in patients with sta-
ble CAD or ticagrelor 90 mg twice daily in patients with 
ACS for 1 year, followed by aspirin 75–100 mg once daily 
alone for the following 12 months (from 12 to 24 months 
after PCI). Patients were followed up at 30  days and 3, 
6, 12, 18 and 24  months after the index procedure. An 
illustration of the antiplatelet strategy used in the trial is 
shown in Fig. 1.
The trial was approved by the institutional review 
board at each center and followed the ethical principles 
of the Declaration of Helsinki. All patients provided writ-
ten informed consent prior to participation in the trial.
Patients
The GLOBAL LEADERS trial randomized 15,991 par-
ticipants -23 patients withdrew consent and requested 
the deletion of their data from the database [7] -DM 
and CKD status was unavailable in 96 patients, leaving 
15,872 patients (99.2%) for the present analyses. Patients 
with DM or CKD were pre-specified subgroups of the 
GLOBAL LEADERS study [13]. However, the analyses 
with significantly lower rates of POCE (5.8% versus 11.0%, HR 0.49; 95% CI [0.29–0.82], p = 0.007,  pinteraction = 0.040) and 
NACE (5.8% versus 11.2%, HR 0.48; 95% CI [0.29–0.82], p = 0.007,  pinteraction = 0.013) in the second year.
Conclusion: Among patients with both DM and CKD, ticagrelor monotherapy was not associated with lower rates of 
all‑cause death or new Q‑wave, or major bleeding complications; however, it was associated with lower rates of POCE 
and NACE. These findings should be interpreted as hypothesis‑generating.
Clinical Trial Registration: ClinicalTrials.gov (NCT01813435).
Keywords: Chronic kidney disease, Diabetes mellitus, Percutaneous coronary intervention, DAPT, Ticagrelor, Aspirin‑
free antiplatelet strategies
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of current analyses were not pre-specified. As pre-spec-
ified in the trial protocol, CKD was defined at the time of 
randomization, using an eGFR cut-off of 60 ml/min/1.73 
 m2 (stage III to V CKD by KDIGO classification), calcu-
lated according to the Modification of Diet in Renal Dis-
ease (MDRD) equation [14]. A sensitivity analysis was 
performed by defining CKD using an eGFR cut-off of 
90 ml/min/1.73  m2 (equivalent to the stage II to V CKD 
by KDIGO classification, results shown in Additional 
file 1: Table S3). The status of DM was site-reported and 
defined at the time of randomization [13]. The PRECISE-
DAPT score was calculated by the online calculator [15].
Outcomes
The events definitions have been reported previously 
[16]. The primary endpoint was a composite of all-cause 
mortality or new Q-wave myocardial infarction (MI). The 
key secondary safety endpoint was investigator-reported 
Bleeding Academic Research Consortium (BARC) type 3 
or 5 bleeding [17]. Other secondary endpoints included: 
individual components of the primary endpoint (all-
cause death, new Q-wave MI), individual components 
of key secondary safety endpoint (BARC defined bleed-
ing type 3 or type 5 bleeding), any stroke, site-reported 
MI, any revascularization, target vessel revascularization 
(TVR), definite stent thrombosis (ST) defined accord-
ing to the Academic Research Consortium criteria [18]. 
The site-reported MI was defined according to the Third 
Universal Myocardial Infarction definition, as pre-spe-
cific in the study protocol [13]. The patient-oriented 
composite endpoint (POCE)—advocated by Academic 
Research Consortium (ARC)-2, and net adverse clinical 
events (NACE) were explored up to two years [17, 19]. 
POCE was defined as the composite of all-cause death, 
any stroke, site-reported MI (including periprocedural 
or spontaneous with ST elevation MI [STEMI] or non-
ST-segment elevation MI [NSTEMI]) and any revascu-
larization (re-PCI or coronary artery bypass graft surgery 
[CABG] in the target or non-target vessel) [19], whereas 
NACE combined POCE with BARC type 3 or 5 bleeding 
events. Composite endpoints were analyzed hierarchi-
cally and the individual components of the composite 
endpoints were reported non-hierarchically.
Statistical analysis
All the analyses were performed by the intention-to-
treat principle. Continuous variables with normal dis-
tribution are expressed as mean ± standard deviation 
and those with skewed distribution are expressed as 
median ± interquartile range. Categorical variables are 
presented as counts and percentages. Means of 2 contin-
uous variables were compared by independent samples 
Student’s t-test or Mann–Whitney U test when appropri-
ate. The frequencies of categorical variables were com-
pared using Fisher’s exact test. Survival was estimated 
by the Kaplan–Meier method. The impacts of CKD and 
DM on outcomes were assessed in the multivariable Cox 
proportional hazards model. The covariates in the multi-
variable model included age, sex, body mass index (BMI), 
clinical presentation (ACS versus stable CAD), stroke, 
peripheral vascular disease (PVD), chronic obstructive 
pulmonary disease (COPD), hypertension, previous PCI, 
hypercholesterolemia, current smoking status, treat-
ment regimen (experimental versus. reference regimen), 
complex PCI, ACEI or ARB, beta-blockade, statin, Paris 
thrombotic risk score, and Paris bleeding risk score. A 
sensitivity analysis was conducted by adjusting the Cox 
proportional hazards model with the Propensity score 
(Propensity score was calculated by including all vari-
ables in Table 1). The detailed methods to calculate Pro-
pensity score and the results of the sensitivity analysis 
were shown in Additional file 1: Methods and Table S8. 
Cox proportionality assumptions were checked by using 
the Schoenfeld residuals against the transformed time 
and the assumptions were met in all models. Land-
mark analyses were performed at 365 days of follow-up, 
Fig. 1 Illustration of the antiplatelet strategy in the GLOBAL LEADERS trial
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which was based on the prespecified landmark point in 
the GLOBAL LEADERS design. So far, there have been 
24 subgroup analyses of the GLOBAL LEADERS trial. 
However, taking into account the post hoc and explora-
tory nature of the analysis, there was no formal correc-
tion for multiple testing [20]. Analyses were performed 
using R-project (R Foundation, Vienna, Austria). A 
two-sided p value less than 0.05 was considered as statis-
tical significance.
Results
Patients and outcomes according to DM and CKD status
A total of 15,872 patients from the GLOBAL LEADERS 
trial population were classified according to the DM and 
Table 1 Baseline Characteristics according to DM/CKD status
Data are n/N (%), unless otherwise specified. Denominators vary because medical history data were incomplete
* The comparison between DM-/CKD + and DM + /CKD + was statistically significant
Characteristic DM (-) CKD (-) DM ( +) CKD (-) DM (-) CKD ( +) DM ( +) CKD ( +)
n = 10,513 n = 3189 n = 1332 n = 838
Age, years (SD) 63.0 (10.2) 65.0 (9.2) 71.5 (9.5) 71.3 (8.8)*
Male 8387/10,513 (79.8%) 2445/3189 (76.7%) 830/1332 (62.3%) 518/838 (61.8%)*
Mean body‑mass index, kg/m2 (SD) 27.65 (4.3) 29.59 (5.0) 28.01 (4.5) 29.91 (5.0)*
Medical history
 Insulin‑dependent diabetes mellitus 0/10,513 (0.0%) 869/3155 (27.3%) 0/1332 (0.0%) 352/836 (42.0%)
 Hypertension 7047/10,471 (67.3%) 2721/3185 (85.4%) 1118/1329 (84.1%) 770/838 (91.9%)*
 Hypercholesterolemia 6771/10,196 (64.4%) 2421/3085 (75.9%) 879/1286 (66.0%) 634/813 (75.7%)*
 Current smoker 3135/10,513 (29.8%) 686/3189 (21.5%) 207/1332 (15.5%) 110/838 (13.1%)*
 Previous stroke 209/10,501 (2.0%) 120/3182 (3.8%) 48/1330 (3.6%) 44/838 (5.3%)*
 Previous peripheral vascular disease 480/10,433 (4.6%) 273/3158 (8.6%) 121/1317 (9.1%) 126/826 (15.0%)*
 Chronic obstructive pulmonary disease 485/10,474 (4.6%) 179/3174 (5.6%) 86/1327 (6.5%) 69/828 (8.2%)*
 Previous myocardial infarction 2265/10,487 (21.5%) 815/3176 (25.6%) 344/1330 (25.8%) 269/835 (32.1%)*
 Previous PCI 3107/10,504 (29.6%) 1249/3186 (39.2%) 471/1331 (35.4%) 372/838 (44.4%)*
 Previous CABG 477/10,506 (4.5%) 266/3185 (8.4%) 91/1331 (6.8%) 107/838 (12.8%)*
 Previous bleeding 59/10,504 (0.6%) 18/3181 (0.6%) 15/1331 (1.1%) 6/838 (0.7%)
Clinical presentation
 Stable coronary artery disease 5298/10,513 (50.4%) 1913/3189 (60.0%) 690/1332 (51.8%) 514/838 (61.3%)
 Acute coronary syndrome 5215/10,513 (49.6%) 1276/3189 (40.0%) 642/1332 (48.2%) 324/838 (38.7%)
Complex PCI 2976/10,513 (28.3%) 934/3189 (29.3%) 377/1332 (28.3%) 263/838 (31.4%)
 Multivessel PCI 2216/10,513 (21.1%) 671/3189 (21.0%) 282/1332 (21.2%) 189/838 (22.6%)
 Lesion treated ≥ 3 851/10,513 (8.1%) 266/3189 (8.3%) 113/1332 (8.5%) 68/838 (8.1%)
 Stent implanted ≥ 3 1793/10,513 (17.1%) 568/3189 (17.8%) 235/1332 (17.6%) 162/838 (19.3%)
 Bifurcation PCI with ≥ 2 stents 323/10,513 (3.1%) 88/3189 (2.8%) 31/1332 (2.3%) 28/838 (3.3%)
 Total stent length >60 mm 1346/10,513 (12.8%) 437/3189 (13.7%) 180/1332 (13.5%) 106/838 (12.7%)
 Total Stent Length (SD) 35.2 (25.1) 36.0 (25.2) 35.7 (25.8) 36.3 (26.2)
 Medications on discharge
 ACE‑inhibition and/or ARB 6346/10,450 (60.4%) 1986/3162 (62.3%) 730/1320 (54.8%) 457/826 (54.5%)
 Beta‑blockade 8194/10,452 (77.9%) 2577/3163 (80.8%) 1069/1321 (80.3%) 669/826 (79.8%)
 Statin 9718/10,459 (92.4%) 2916/3168 (91.4%) 1212/1322 (91.0%) 764/827 (91.2%)
Paris bleeding risk score [31] (IQR) 3 (2,4) 3 (2,4) 6 (5,7) 6 (5,7)*
 Paris thrombotic risk score (IQR) 2 (0,4) 3 (2,4) 4 (2,7) 5 (4,7)*
 Paris bleeding risk score ≥ 8 100/10,039 (1.0%) 41/3060 (1.3%) 269/1288 (20.9%) 189/803 (23.5%)*
Paris thrombotic risk score ≥ 5 140/10,506 (1.3%) 655/3185 (20.8%) 243/1331 (18.3%) 615/838 (73.4%)*
PRECISE DAPT score [15] (IQR) 14 (9,19) 15 (10,20) 27 (23,32) 29 (24,34)*
 PRECISE DAPT score ≥ 25 731/9849 (7.4%) 323/3007 (10.7%) 846/1266 (66.8%) 567/799 (71.0%)*
Antiplatelet therapy
 Reference treatment strategy 5297/10,513 (50.4%) 1575/3189 (49.4%) 662/1332 (49.7%) 410/838 (48.9%)
 Experimental treatment strategy 5216/10,513 (49.6%) 1614/3189 (50.6%) 670/1332 (50.3%) 428/838 (51.1%)
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CKD status as follows: DM-/CKD- (n = 10,513), DM + /
CKD- (n = 3189), DM-/CKD + (n = 1332), and DM + /
CKD + (n = 838). Baseline characteristics are presented 
in Table 1. Patients with DM + /CKD + were older, more 
often had a prior history of revascularization (PCI or 
CABG), previous stroke, previous MI, PVD, COPD. In 
DM + /CKD + patients, the percentages of patients who 
had a Paris bleeding risk score ≥ 8 (23.5%), thrombotic 
risk score ≥ 5 (73.4%), and PRECISE-DAPT score ≥ 25 
(71.0%) were higher compared with DM-/CKD- patients.
The DM + /CKD + patients had a 2.16-fold higher 
incidence of the primary endpoint at 24  months, com-
pared with the DM-/CKD- individuals (9.5% versus 3.1%, 
adjusted HR 2.16; 95% CI [1.66–2.80], Table 2). The DM-/
CKD + (6.9%, adjusted HR 1.53; 95% CI [1.20–2.80]) 
and DM + /CKD- patients (4.6%, adjusted HR 1.40; 95% 
CI [1.15–1.72]) had intermediate risk profile. With the 
DM + /CKD + patients exhibiting the highest risk, the 
hazard ratio gradually decreased in the order of DM-/
CKD + , DM + /CKD- and DM-/CKD-  (PTrend < 0.001; 
Fig. 2 and Table 2). Similar trends were observed in the 
key secondary endpoint (Bleeding Academic Research 
Consortium [BARC] type 3 or 5 bleeding), and other sec-
ondary endpoints including all-cause mortality, stroke, 
MI, revascularization, TVR, POCE, and NACE (Table 2).
Outcomes of experimental versus reference regimen 
according to CKD and DM status
Compared with the reference regimen (DAPT for 
12 months and then aspirin for 12 months), the experi-
mental regimen (DAPT for 1 month followed by ticagre-
lor monotherapy for 23 months) did not show lower rates 
of the primary or the key safety secondary endpoints 
in DM + /CKD + patients, or in any of the other three 
Table 2 Clinical outcomes according to DM/CKD subgroup
Data are n/N (%), unless otherwise specified
MI, Myocardial ischemia
TVR, Target vessel revascularization
MACE, all-cause death, any stroke, or non-fatal new Q-wave MI
POCE, all-cause death, any stroke, any myocardial infarction or any revascularization
BARC, Bleeding Academic Research Consortium
NACE, POCE and BARC 3 or 5 bleeding
Adjusted to age, sex, body mass index (BMI), clinical presentation (ACS versus stable CAD), stroke, peripheral vascular disease (PVD), chronic obstructive pulmonary 
disease (COPD), previous PCI, hypercholesterolemia, hypertension, current smoking status, treatment regimen (experimental versus. reference regimen), complex PCI, 
ACEI or ARB, beta-blockade, statin, Paris thrombotic risk score, and Paris bleeding risk score
DM (-) CKD (-) DM ( +) CKD (-) DM (-) CKD ( +) DM ( +) CKD ( +) Ptrend
n = 10,513 HR (95% CI) HR (95% CI) n = 1332 HR (95% CI) n = 838 HR (95% CI)
All‑cause mortality or New 
Q‑wave MI
330 (3.1%) 1.00 (Ref ) 1.32 (1.07–1.61) 92 (6.9%) 1.54 (1.21–2.49) 80 (9.5%) 1.91 (1.47–2.49)  < 0.001
 All‑cause mortality 226 (2.1%) 1.00 (Ref ) 1.37 (1.08–1.75) 74 (5.6%) 1.67 (1.27–2.81) 67 (8%) 2.09 (1.55–2.81)  < 0.001
 New Q‑wave MI 108 (1%) 1.00 (Ref ) 1.29 (0.9–1.86) 19 (1.4%) 1.19 (0.72–2.3) 13 (1.6%) 1.26 (0.69–2.3) 0.257
Stroke 78 (0.7%) 1.00 (Ref ) 1.86 (1.28–2.71) 18 (1.4%) 1.17 (0.68–3.48) 19 (2.3%) 2.04 (1.19–3.48) 0.013
MI 273 (2.6%) 1.00 (Ref ) 1.48 (1.18–1.85) 52 (3.9%) 1.61 (1.18–3.49) 53 (6.3%) 2.54 (1.85–3.49) 0.001
Any Revascularization 917 (8.7%) 1.00 (Ref ) 1.26 (1.11–1.43) 129 (9.7%) 1.17 (0.96–1.91) 113 (13.5%) 1.55 (1.26–1.91)  < 0.001
 TVR 466 (4.4%) 1.00 (Ref ) 1.5 (1.27–1.78) 71 (5.3%) 1.28 (0.99–2.37) 67 (8.0%) 1.8 (1.38–2.37)  < 0.001
Definite stent thrombosis 82 (0.8%) 1.00 (Ref ) 1.08 (0.69–1.7) 13 (1.0%) 1.43 (0.78–2.23) 6 (0.7%) 0.94 (0.4–2.23) 0.569
MACE 394 (3.7%) 1.00 (Ref ) 1.43 (1.19–1.71) 101 (7.6%) 1.4 (1.11–2.42) 93 (11.1%) 1.9 (1.49–2.42)  < 0.001
POCE 1242 (11.8%) 1.00 (Ref ) 1.3 (1.17–1.45) 219 (16.4%) 1.3 (1.12–2.06) 194 (23.2%) 1.75 (1.49–2.06)  < 0.001
NACE 1360 (12.9%) 1.00 (Ref ) 1.27 (1.15–1.41) 245 (18.4%) 1.29 (1.12–2.03) 213 (25.4%) 1.74 (1.49–2.03)  < 0.001
BARC 3 or 5 bleeding 188 (1.8%) 1.00 (Ref ) 1.05 (0.78–1.41) 44 (3.3%) 1.18 (0.83–2.39) 37 (4.4%) 1.64 (1.12–2.39) 0.02
 BARC 5 bleeding 27 (0.3%) 1.00 (Ref ) 0.51 (0.2–1.3) 8 (0.6%) 1.16 (0.5–2.09) 5 (0.6%) 0.71 (0.24–2.09) 0.704
 BARC 3 bleeding 173 (1.6%) 1.00 (Ref ) 1.12 (0.83–1.52) 41 (3.1%) 1.22 (0.85–2.71) 35 (4.2%) 1.84 (1.25–2.71) 0.005
   BARC 3a bleeding 77 (0.7%) 1.00 (Ref ) 1.31 (0.85–2.01) 25 (1.9%) 1.64 (1.02–2.63) 13 (1.6%) 1.42 (0.76–2.63) 0.054
   BARC 3b bleeding 74 (0.7%) 1.00 (Ref ) 1.01 (0.62–1.64) 17 (1.3%) 1.29 (0.73–3.71) 14 (1.7%) 2.02 (1.1–3.71) 0.043
   BARC 3c bleeding 38 (0.4%) 1.00 (Ref ) 0.78 (0.37–1.65) 3 (0.2%) 0.38 (0.11–4.56) 10 (1.2%) 2.11 (0.98–4.56) 0.524
BARC 2 bleeding 489 (4.7%) 1.00 (Ref ) 1 (0.83–1.21) 82 (6.2%) 1.07 (0.84–1.52) 54 (6.4%) 1.14 (0.85–1.52) 0.388
BARC 2, 3 or 5 bleeding 647 (6.2%) 1.00 (Ref ) 1.01 (0.86–1.19) 118 (8.9%) 1.11 (0.9–1.62) 84 (10%) 1.27 (1–1.62) 0.063
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subgroups (Fig. 3a, b, and Table 3). Although not statis-
tically significant, the absolute risk reduction of the pri-
mary endpoint gradually increased in the following order 
of DM-/CKD-, DM-/CKD + , DM + /CKD-, DM + /
CKD + (0.3%, 1.0%, 1.1%, and 2.3%) in patients receiving 
the experimental regimen. 
Among the DM + /CKD + patients, the experimental 
regimen was associated with lower rates of POCE (20.6% 
versus 25.9%, HR 0.74; 95%CI [0.55–0.99], p = 0.043, 
 pinteraction = 0.155) and NACE (22.7% versus 28.3%, HR 
0.75; 95%CI [0.56–0.99], p = 0.044,  pinteraction = 0.310), 
which were mainly driven by lower rates of any revascu-
larization (11.5% versus 15.6%; adjusted HR 0.67; 95%CI 
[0.45–0.99], P = 0.042,  pinteraction = 0.286) and TVR (6.1% 
versus 10.0%; adjusted HR 0.56; 95%CI [0.33–0.93], 
P = 0.026,  pinteraction = 0.238; Fig.  3c–f, and Table  3), as 
compared with the reference regimen. The numbers 
needed-to-treat to reduce a POCE, NACE, any revascu-
larization and TVR event were 19, 18, 24 and 25, respec-
tively. Additional sensitivity analyses were performed to 
investigated the treatment effects of experimental regi-
men in patients who were adherent to the allocated med-
ications, in ACS patients, and in Stable CAD patients, 
respectively. The results are shown in Additional file  1: 
Table S5–S7.
Landmark analysis
Given that according to the study protocol, the refer-
ence treatment strategy arm received conventional 
12-month DAPT (Clopidogrel/Ticagrelor was stopped at 
12-month) followed by 12- month aspirin monotherapy, 
we performed a landmark analysis at 365  days after the 
index procedure to specifically analyze the impact of 
P2Y12 discontinuation in the reference strategy. The 
results showed that among DM + /CKD + patients, 
between 0–365  days after randomization, the experi-
mental and reference regimen had similar rates of all 
investigated endpoints (Additional file  1: Table  S4 and 
Fig. S2 ), whereas between 365–730  days after rand-
omization, compared with the reference regimen, the 
experimental regimen was associated with significantly 
lower rates of POCE (5.8% versus 11.0%, HR 0.49; 95% 
CI [0.29–0.82], p = 0.007,  pinteraction = 0.040), NACE (5.8% 
versus 11.2%, HR 0.48; 95% CI [0.29–0.82], p = 0.007, 
 pinteraction = 0.013), any revascularization (2.3% versus 
6.6%, adjusted HR 0.29; 95% CI [0.13–0.65], P = 0.003, 
 pinteraction = 0.056) and TVR (1.4% versus 2.9%, adjusted 
HR 0.29; 95% CI [0.09–0.91], P = 0.033,  pinteraction = 0.112) 
(Table 4 and Additional file 1: Fig. S2). The rate of BARC 
type 3 or 5 bleeding events (0.7% versus 1.5%, P = 0.331) 
was similar between the two antiplatelet regimens 
between 365 and 730 days after randomization. 
Discussion
The main findings of this post hoc analysis of the 
GLOBAL LEADERS trial can be summarized as follows:
1) The concomitant presence of DM and CKD is not 
uncommon in an “all-comers” trial, representing 21% 
of the patients with DM, and 5% of the overall study 
population.
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Fig. 2 Clinical events shown by Kaplan–Meier curves. a All‑cause mortality and new Q‑wave MI; b Bleeding Academic Research Consortium 
(BARC)–defined type 3 or 5 bleeding events;
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Fig. 3 Kaplan–Meier curves showing the clinical events according to treatment regimen and DM/CKD status. a All‑cause mortality and new 
Q‑wave MI; b Bleeding Academic Research Consortium (BARC)–defined type 3 or 5 bleeding events; c Any revascularization; d Target vessel 
revascularization; e POCE; f NACE;
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2) Up to two years post-PCI, there was a gradient in the 
thrombotic and bleeding risk among patients strati-
fied according to the presence or absence of DM or 
CKD, with the highest risk found among subjects 
having both comorbidities.
3) In patients with both DM and CKD, the primary 
endpoint (all-cause mortality or new Q-wave MI) or 
the key safety secondary endpoint (BARC type 3 or 
5 bleeding) did not differ significantly between the 
experimental and the reference regimens. Notwith-
standing, the experimental regimen was associated 
with lower rates of POCE and NACE, mainly driven 
by repeat revascularization.
Table 3 Forest plot of the endpoints according to treatment regimen and DM/CKD status
Adjusted to age, sex, body mass index (BMI), clinical presentation (ACS versus stable CAD), stroke, peripheral vascular disease (PVD), chronic obstructive pulmonary 
disease (COPD), previous PCI, hypercholesterolemia, hypertension, current smoking status, complex PCI, ACEI or ARB, beta-blockade, statin, Paris thrombotic risk 
score, and Paris bleeding risk score
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The prevalence and prognosis of CAD patients with DM 
and CKD
Both DM and CKD are independently associated with 
an increased risk of cardiovascular ischemic events, 
which can be attributed to patients’ pro-thrombotic and 
pro-inflammatory status [2, 3]. These two risk factors of 
coronary heart disease have also been shown to synergis-
tically amplify the hazards when they co-exist. Reports 
published nearly two decades ago showed that mortal-
ity rates one year after successful PCI in DM patients 
with moderate and severe CKD were respectively, 5- and 
12-times higher when compared to patients with normal 
renal function [21]. A subgroup analysis of the PLATO 
trial -a trial conducted over a decade ago [22], showed 
that patients with the combination of DM and CKD had 
a greater than threefold increase in the risk of mortal-
ity [6]. In the contemporary GLOBAL LEADERS trial, 
we found that despite the progressive improvements in 
stent design and secondary preventive pharmacothera-
pies, patients with both DM and CKD still had a 2.1-fold 
higher risk of mortality, 1.6-fold higher risk of repeat 
revascularization, and 1.6-fold higher risk of BARC 3 or 
Table 4 Forest plot of the endpoints by landmark analyses (365-730 days)
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5 bleeding, compared with patients without these risk 
factors. Although these results suggest that the hazards 
of having both comorbidities have somewhat attenuated 
over the years, patients with both DM and CKD were still 
at high risk of ischemic and bleeding events. These obser-
vations underscore the need to identify novel therapeu-
tic approaches that can reduce the risks in this specific 
population.
In the current analysis, we found that 20.8% (838/4027) 
of DM patients had CKD. This proportion is relatively 
similar among some pivotal cardiovascular RCTs. For 
instance, in the PLATO trial that investigated adjunctive 
antiplatelet pharmacotherapy in patients with acute coro-
nary syndromes [6], the percentage of DM patients who 
had CKD was 22.0% (1058/3807). In the SYNTAX trial, 
which tested the optimal revascularization technique in 
patients with complex coronary lesions, the proportion 
was 20.8% (85/408, unpublished data). However, data 
from a German national database [23] and two dedicated 
registries (Diabetes-Patienten-Verlaufsdokumentation 
and DIabetes Versorgungs-Evaluation) [24] suggested 
that approximately 40–50% of individuals with DM have 
comorbid CKD. Therefore, when compared with these 
population-based studies, the DM + /CKD + popula-
tion in the GLOBAL LEADERS and some cardiovascu-
lar RCTs might be underrepresented, or conversely these 
registries with specific inclusion criteria may have an 
overrepresentation of the syndrome.
DAPT strategy for DM + /CKD + patients (0–1 year post PCI)
The optimal DAPT strategy for DM + /CKD + patients 
remains a matter of debate owing to scarce evidence. 
Generally, DM + /CKD + patients are at high bleeding 
risk [25]. In the GLOBAL LEADERS population, 71.0% 
of the DM + /CKD + patients had a PRECISE-DAPT 
score of 25 or more. As suggested by the 2018 European 
Society of Cardiology guidelines on Myocardial Revascu-
larization [1], patients with high bleeding risk (PRECISE-
DAPT score of 25 as the cutoff point) should discontinue 
DAPT after 3- (in stable CAD) or 6-months (in ACS) 
post-PCI to reduce the risk of bleeding; however, DM + /
CKD + patients were also at high thrombotic risk (73.4% 
of these patients had a Paris thrombotic risk score of > 5). 
Indeed, a short DAPT strategy would reduce bleeding 
events, but at the same time, might plausibly augment the 
thrombotic risk [26, 27].
Considering the dilemma of DAPT duration, the strat-
egy of ticagrelor monotherapy has been proposed as a 
means to reduce the risk of bleeding while maintain-
ing a similar risk of thrombotic events after PCI. The 
TWILIGHT trial [8, 28], in which either DM or CKD 
constituted an enrichment criteria according to the pro-
tocol (2620 pts with DM and 1145 pts with CKD in the 
TWILIGHT trial), has compared 3-month DAPT fol-
lowed by 12-month ticagrelor monotherapy after PCI 
with standard DAPT strategy. The results showed a sig-
nificant reduction of BARC type 2, 3 or 5 bleeding events 
in the ticagrelor monotherapy arm, while demonstrating 
a similar risk of the composite secondary endpoint of 
all-cause death, non-fatal MI, or stroke. Compared with 
the TWILIGHT trial, the current study showed that in 
DM + /CKD + patients, ticagrelor monotherapy strategy 
in the first year had similar rates of all-cause mortality, 
MI or revascularization, as well as the rate of BARC type 
2, 3 or 5 bleeding events, compared with the standard 
DAPT strategy. These results showed that although the 
thrombotic risks were higher in DM + /CKD + patients, 
ticagrelor monotherapy (or the “aspirin-free strategy”) 
might not be associated with increased thrombotic 
events compared with the standard DAPT.
Prolonged ticagrelor monotherapy for secondary 
prevention (1 year post PCI)
To date, there is no evidence elaborating the optimal 
antiplatelet medication for the secondary prevention 
of the DM + /CKD + patients post PCI. Alike other 
patients, those patients are now generally treated with 
aspirin lifelong for secondary prevention. Whether tica-
grelor represents a worse, alternative, or better choice 
still debatable. In DM patients with stable CAD and a 
history of PCI), results of the THEMIS-PCI trial [29, 
30] have demonstrated that compared to aspirin for 
secondary prevention, ticagrelor reduced the ischemic 
endpoint of cardiovascular death, MI, and stroke with 
modestly increasing the bleeding events. In total, ticagre-
lor improved the net clinical benefit (9.3% versus 11.0%, 
HR = 0.85, 95% CI 0.75–0.95, p = 0.005) in the THEMIS-
PCI population. For the DM + /CKD + patients, whether 
it is legitimate to simply apply to the recommendation for 
DM patients (such as the results of the TWILIGHT and 
the THEMIS-PCI trial), is somehow based on empiri-
cal experiences. So far, there is no specific narrative in 
the consensus or guideline helping the clinician to make 
the decision. The current analysis found that in DM + /
CKD + patients, compared with aspirin monotherapy, 
the ticagrelor monotherapy had similar BARC type 2, 
3 or 5 bleeding events, meanwhile, was associated with 
lower rates of POCE and NACE, which were predomi-
nantly confined to reductions in any revascularization or 
TVR events that occurred during the second year of the 
trial.
Legitimately, like the THEMIS-PCI trial, prolonging 
the use of ticagrelor would increase the risk of bleeding. 
The neutral statistical findings in our analysis regarding 
BARC type 2, 3 or 5 bleeding events might be due to play 
of chance or the relatively low sample size (although it is 
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one of the largest trials investigating such issue). How-
ever, the improved net clinical benefit of the ticagrelor 
monotherapy shown in our analysis and the THEMIS-
PCI trial supported that prolonged ticagrelor might 
be a reasonable treatment option for DM or DM + /
CKD + patients regarding secondary prevention. Of 
note, given the inherent limitations of sub-analyses, our 
findings cannot make strong inferences nor necessitate 
changes in clinical practice.
Limitations
The following limitations have to be considered in the 
present analysis. (1) Given that the two antiplatelet strat-
egies did not differ significantly with regard to rates of 
the primary endpoint in the overall trial [7], and the post 
hoc nature of the study, all reported analyses have to be 
considered strictly exploratory. (2) The randomization in 
the GLOBAL LEADERS trial was not stratified according 
to the presence of DM or CKD, therefore some imbal-
ances between the randomized groups may exist among 
the four sub-categories. Although multivariable adjusted 
Cox proportional hazard models were performed to try 
to estimate the true treatment effects of the different 
regimens, the usual deficiency for observational stud-
ies exists, such as the inability to include all relevant 
confounders especially those unmeasured, causing bias 
which cannot be adjusted.
Conclusions
The present analysis showed that in a contemporary 
PCI cohort, patients with DM and CKD are at mark-
edly increased risk of long-term thrombotic and bleed-
ing events, compared with patients one or neither of 
these risk factors. In patients with both comorbidities, 
ticagrelor monotherapy was not associated with a lower 
rate of the primary endpoint (all-cause mortality or 
new Q-wave MI) or bleeding (BARC type 3 or 5 bleed-
ing), but was associated with a lower rate of POCE and 
NACE, which was mainly driven by the lower rate of any 
revascularization.
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